Advertisement

Cambridge biopharmaceutical firm Galenea Corp. has won a $4.5 million grant from the National Institute of Mental Health for a technology platform aimed at identifying compounds to treat schizophrenia. The grant, the second of its kind, is funded by the American Recovery and Reinvestment Act of 2009.

The grant was awarded for the company’s MANTRA (Multiwell, Automated NeuroTRansmission Assay) technology platform that Galenea reports has potential to treat other psychiatric and neurodegenerative diseases linked to synaptic transmission, the communication of brain neurons.

SOURCE

Advertisement
Advertisement